Watson M, Vickroy T W, Roeske W R, Yamamura H I
Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):569-74. doi: 10.1016/0278-5846(85)90018-1.
The novel antimuscarinic compound pirenzepine (PZ) has generated considerable interest in the basis and the implications of muscarinic acetylcholine receptor (mAChR) heterogeneity. [3H]PZ has been used extensively to identify and characterize the putative M1 (high affinity for PZ) mAChR subtype, which predominates in central nervous system (CNS) and ganglia. The heterogeneity sensed by PZ is not identical to the heterogeneity sensed by agonists. Differences in effector coupling do not necessarily provide a simple explanation for the molecular basis of these putative M1 and M2 subtypes. Therapeutic and untoward effects of muscarinic drugs may be mediated by independent mAChR subpopulations which may be pharmacologically exploited to produce more highly selective as well as efficacious new drugs.
新型抗毒蕈碱化合物哌仑西平(PZ)引起了人们对毒蕈碱型乙酰胆碱受体(mAChR)异质性的基础及影响的极大兴趣。[3H]PZ已被广泛用于识别和表征假定的M1(对PZ具有高亲和力)mAChR亚型,该亚型在中枢神经系统(CNS)和神经节中占主导地位。PZ所感知的异质性与激动剂所感知的异质性并不相同。效应器偶联的差异不一定能为这些假定的M1和M2亚型的分子基础提供简单解释。毒蕈碱药物的治疗作用和不良作用可能由独立的mAChR亚群介导,这些亚群在药理学上可被利用来生产更具选择性且有效的新药。